From: A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease
Tolvaptan
No Tolvaptan
Differencea
Life yearsa
27.4
26.6
0.7
 CKD stage G1
1.3
1.0
0.4
 CKD stage G2
4.9
3.9
 CKD stage G3
7.3
5.9
1.5
 CKD stage G4
3.2
2.9
0.3
 ESRD
10.6
13.0
−2.4